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TrabectedinAbstract Aim: This randomised phase III trial evaluated ﬁrst-line trabectedin versus doxoru-
bicin-based chemotherapy (DXCT) in patients with advanced/metastatic translocation-related
sarcomas (TRS).
Methods: Patients were randomly assigned (1:1) to receive trabectedin 1.5 mg/m2 24-h intra-
venous (i.v.) infusion every 3 weeks (q3wk) (Arm A), or doxorubicin 75 mg/m2 i.v. q3wk, or
doxorubicin 60 mg/m2 i.v. plus ifosfamide (range, 6–9 g/m2) i.v. q3wk (Arm B). Progres-
sion-free survival (PFS) by independent review was the primary efﬁcacy end-point.
Results: One hundred and twenty-one patients were randomised; 88 of them had TRS con-
ﬁrmed by central pathology review (efﬁcacy population). Twenty-nine PFS events were: +33 4
1138 J.-Y. Blay et al. / European Journal of Cancer 50 (2014) 1137–1147assessed by independent review (16 with trabectedin; 13 with DXCT). PFS showed non-signif-
icant difference between arms (stratiﬁed log rank test, p = 0.9573; hazard ratio = 0.86,
p = 0.6992). At the time of this analysis, 63.9% and 58.3% of patients were alive in trabectedin
and DXCT arms, respectively. There was no statistically signiﬁcant difference in survival
curves. Response rate according to Response Evaluation Criteria in Solid Tumours (RECIST)
v.1.0 was signiﬁcantly higher in DXCT arm (27.0% versus 5.9%), but response according to
Choi criteria showed fewer differences between treatment arms (45.9% versus 37.3%). Safety
proﬁle was as expected for both arms, with higher incidence of severe neutropenia, alopecia
and mucositis in the DXCT arm.
Conclusion: Neither trabectedin nor doxorubicin-based chemotherapy showed signiﬁcant
superiority in the ﬁrst-line treatment of patients with advanced translocation-related sarcoma.
 2014 The Authors. Published by Elsevier Ltd.Open access under CC BY-NC-ND license. 1. Introduction
Trabectedin is a marine-derived antineoplastic agent
active against advanced soft tissue sarcoma (STS) [1–4]
which has shown relevant antitumor activity in prospec-
tive and retrospective series of patients with myxoid/
round cell liposarcoma (MRCL) resistant or relapsed
to conventional chemotherapy [5–7]. The genetic hall-
mark of MRCL is translocation t(12:16)(q13;p11) [8],
which produces the chimeric fusion protein FUS-CHOP
that binds to speciﬁc DNA promoters, leading to dereg-
ulated expression of downstream proteins which
eventually cause neoplastic transformation [9]. In vitro,
trabectedin interferes with the binding of this fusion
protein to DNA promoters [10]. Based on structural
and functional similarities of chimeric fusion proteins
that generate new transcription factors, it was hypothe-
sised that trabectedin could induce in other transloca-
tion-related sarcomas (TRS) eﬀects similar to those
described in MRCL. Indeed, trabectedin was eﬃcacious
in some patients with prevalent TRS: synovial sarcoma,
alveolar soft part sarcoma and endometrial stromal sar-
coma [7,11–13].
As preclinical and preliminary clinical data pointed
to a potentially increased eﬃcacy of trabectedin in
MRCL and other TRS, this randomised trial compared
trabectedin with standard ﬁrst-line treatment (doxorubi-
cin-based chemotherapy, DXCT) in patients with con-
ﬁrmed locally advanced unresectable or metastatic
TRS. This is the ﬁrst randomised trial performed in this
subtype of STS.2. Patients and methods
This study was conducted at 22 investigational
sites from United States of America (USA) (n = 8),
France (n = 5), United Kingdom (UK) (n = 4),
Germany (n = 2), Italy (n = 2) and Spain (n = 1)
according to the Declaration of Helsinki, Good
Clinical Practice guidelines and local regulations on
clinical trials, and was approved by respective inde-
pendent ethics committees. Signed informed consent
was obtained from all patients. An Independent DataMonitoring Committee (IDMC) reviewed the study
conduct.
Trial codes were Eudra CT: 2008-002326-11; Clinical-
Trials.gov Identiﬁer: NCT00796120.2.1. Selection of patients
Eligibility criteria included patients P18 year-olds
with initial pathological diagnosis of TRS of following
subtypes: alveolar soft part sarcoma, angiomatoid
ﬁbrous histiocytoma, clear cell sarcoma, desmoplastic
small round cell tumour, low grade endometrial stromal
sarcoma, low grade ﬁbromyxoid sarcoma, myxoid chon-
drosarcoma, MRCL and synovial sarcoma. Ewing’s sar-
coma and dermatoﬁbrosarcoma protuberans were
excluded. Evidence of translocation by ﬂuorescence
in situ hybridisation was not required for patient enrol-
ment into the trial, but only patients with conﬁrmed
translocation were included in the primary study analy-
sis. Patients had to have unresectable locally advanced
or metastatic progressive disease; measurable disease
according to the Response Evaluation Criteria in Solid
Tumours (RECIST v.1.0); Eastern Cooperative Oncol-
ogy Group (ECOG) Performance Status (PS) score
0–2; adequate cardiac function [left ventricular ejection
function (LVEF) within normal limits], and adequate
haematological (haemoglobinP9 g/dl; absolute neutro-
phil count P1.5  109/l; platelets P100  109/l), renal
(serum creatinine 61.5 mg/dl) and hepatic function
[bilirubin 6 upper limit of normal (ULN); aspartate
aminotransferase (AST)/alanine aminotransferase
(ALT) 6 2.5  ULN; alkaline phosphatase (AP)62.5
 ULN (if total AP >2.5  ULN, AP liver fraction
and/or gamma glutamyltransferase and/or 50-nucleotid-
ase had to be 6ULN) and albumin >25 g/l].
Patients were excluded if they had received prior che-
motherapy; prior lesion irradiation (if administered to a
single target lesion); if they had any malignancy within
the previous 5 years (except for basal cell carcinoma or
treated cervical carcinoma in situ), or other relevant clin-
ical conditions (active infection, active viral hepatitis or
chronic liver disease, brain and/or leptomeningeal
metastasis, congestive heart failure or angina pectoris,
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trolled arterial hypertension, arrhythmias or abnormal
LVEF). Pregnant or breast-feeding women or patients
not using appropriate contraceptive measures were
excluded.2.2. Randomisation and treatments
Eligible patients were randomly assigned on a 1:1
basis to receive trabectedin or DXCT. Since single-agent
doxorubicin is the standard treatment for advanced
STS, but some oncologists prefer combination treatment
with ifosfamide, especially for certain tumour types, the
choice of doxorubicin single agent or in combination
was left to the investigators.
Trabectedin was administered at a dose of 1.5 mg/m2
24-h intravenous (i.v.) infusion every 3 weeks (q3wk),
with antiemetic and liver-protecting prophylaxis (dexa-
methasone 20 mg i.v.) 30 min before (Arm A), Doxoru-
bicin was administered at 75 mg/m2 i.v. q3wk, single
agent, or at 60 mg/m2 i.v. plus ifosfamide (range, 6–
9 g/m2) i.v. q3wk, with proper hydration and mesna
administration (Arm B). Permuted-block randomisation
method was used, with stratiﬁcation by baseline ECOG
PS score (0 versus 1–2) and pathological subtype
(MRCL versus other TRS). In Arm A, treatment could
continue until disease progression or discontinuation for
other reasons (e.g. unacceptable toxicity or consent
withdrawal). In Arm B, treatment was stopped if maxi-
mum doxorubicin cumulative dose was reached or if
LVEF was abnormally reduced. In both treatment arms,
a maximum of two dose reductions were allowed in the
event of febrile neutropenia; grade 4 neutropenia
>5 days; grade 4 thrombocytopenia; 3-week delay for
recovery from grade 3/4 ALT or AST; AP or bilirubin
increases of any grade; grade 3/4 nausea/vomiting
(except if reversible with adequate supportive/symptom-
atic therapy), or any other grade 3/4 toxicity.2.3. Eﬃcacy end-points and tumour assessment
Primary eﬃcacy end-point was progression-free
survival (PFS) evaluated in the eﬃcacy population
(i.e. patients randomised with conﬁrmed pathological
diagnosis of TRS and evidence of translocation by
ﬂuorescence in situ hybridisation). PFS and objective
tumour response were assessed by an Independent
External Review Committee (IERC) according to
RECIST v.1.0 [14]. Disease assessments were done
symmetrically across treatment arms; within 4 weeks
before randomisation, every 6 weeks during the ﬁrst
9 months and every 9 weeks thereafter. Exploratory
evaluations according to Choi criteria [15] were prede-
ﬁned per protocol and they were also performed by
the IERC. Secondary analysis of eﬃcacy was based
on the population of all randomised patientsaccording to the investigators’ assessment, as an
intent-to-treat evaluation.2.4. Safety assessment
Safety was evaluated in all patients receiving at least
one dose of study drug, by assessment of adverse events
(AEs), laboratory test results, physical examinations and
vital signs. AEs and laboratory values were graded
according to the National Cancer Institute-Common
Toxicity Criteria for Adverse Events, v.3.0.2.5. Statistical methods
A ﬂexible adaptive design with sample size reassess-
ment, if necessary, was used. A priori assumptions were
a two-sided 5% signiﬁcance level with 80% power,
expected median PFS with DXCT = 11 months and
55% reduction in relative risk of progression or death
[hazard ratio (HR) = 0.45].
At ﬁrst stage, a minimum of 80 evaluable patients
was required [at least 50% (i.e. 40 patients) with
MRCL]. An interim analysis of primary end-point
(PFS) to reject H0 (HR = 1) was planned in the ﬁrst
stage of the trial, with approximately 45 PFS events
assessed by independent review; the adjusted Pocock
boundary p-value to reject H0 with 45 events should
be <0.0432. Comparison between treatment arms was
done by a stratiﬁed log-rank test and signiﬁcance level
determined by actual observed number of events. After
interim analysis, sample size could be increased if the
desired power was not achieved with the observed HR
but was still clinically meaningful.
Response rates were compared by Fisher’s exact test.
Unstratiﬁed log rank test and Cox regression were also
used to evaluate secondary time-to-event end-points,
such as overall survival (OS).
EAST v.4 and SAS v.9.2 were used to calculate
sample size and for all statistical analysis outputs,
respectively.
Patients will be followed for overall survival until
August 2014.3. Results
3.1. Patient disposition
The ﬁrst patient was enrolled on 18th November 2008.
As of 20th February 2012, a total of 121 patients had
been randomised (trabectedin, n = 61; DXCT n = 60)
(Fig. 1); 88 patients were evaluable for the primary eﬃ-
cacy end-point (trabectedin, n = 51; DXCT, n = 37)
and 40 of them had MCRL. Therefore, accrual was put
on hold. At the time of interim analysis (August 2012),
26 PFS events assessed by independent review were
reached (trabectedin, n = 16; DXCT, n = 10). Because
Fig. 1. Disposition of patients (study ﬂow chart, CONSORT diagram).
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a signiﬁcant diﬀerence in PFS of either treatment arm
yielded a too large sample size to be practical (>500
patients), the IDMC advised to end the study in its ﬁrst
stage. Figures shown here (29 PFS events assessed by
independent review: trabectedin, n = 16; DXCT,
n = 13) correspond to last data available in May 2013.
3.2. Patient characteristics
External pathological review did not conﬁrm TRS
diagnosis and/or translocation in 33 of 121 randomised
patients (Table 1). Therefore, primary eﬃcacy popula-
tion consisted of 88 patients: 40 (33.1%) with MRCL
and 48 (39.7%) with other TRS. Patients and disease
characteristics were well balanced between treatment
arms.
3.3. Treatment and dosing
Of 121 randomised patients, 61 were treated with
trabectedin, 57 with DXCT (36 with doxorubicin as
single-agent, and 21 with doxorubicin and ifosfamide
in combination), one patient received epirubicin instead
of DXCT and two were not treated (Fig. 1). At cut-oﬀ
date, two patients in the trabectedin arm (3.3%) contin-
ued therapy. A total of 454 cycles of trabectedin
(median = 5 cycles per patient; range, 1–31) and 264
cycles of DXCT (median = 6 cycles per patient; range,
1–8) were administered.
3.4. Progression-free survival
Primary end-point, PFS in eﬃcacy population
(n = 88), was non-statistically diﬀerent between
treatment arms (stratiﬁed log rank test p = 0.9573)
(Fig. 2a). Hazard ratio was HR = 0.86 (95% conﬁdenceinterval (CI), 0.4–1.8) (p = 0.6992) (Table 2). Secondary
eﬃcacy analysis (n = 121) was also non-statistically sig-
niﬁcant: unstratiﬁed log rank test p = 0.5533 (Fig. 2b)
and HR = 0.85 (95% CI, 0.5–1.5) (p = 0.5551) (Table 2).
Multivariate stepwise Cox regression showed MRCL
subtype as the most favourable prognostic factor, along
with a low number of sites involved and no prior sur-
gery, for patients treated with both trabectedin and
DXCT. Importantly, a high percentage of patients were
censored in both treatment arms rendering the analyses
underpowered (Table 3). Main censoring reason in pri-
mary eﬃcacy population (n = 88) was surgical lesion
removal (curative or palliative) before disease progres-
sion: 23.5% (trabectedin arm) and 16.2% (DXCT arm).
Other frequent censoring reason was the administration
of new anticancer therapy before disease progression:
17.6% (trabectedin arm: chemotherapy in 11.8% and
radiotherapy in 5.9%) and 24.3% (DXCT arm: chemo-
therapy in 18.9% and radiotherapy in 5.4%). Adminis-
tration of other therapies without disease progression
was not addressed in the protocol, but it was assumed
that treating Investigators would manage the patients
in their best beneﬁt.
3.5. Response rate
In eﬃcacy population, RECIST v.1.0 response rate
was signiﬁcantly higher in DXCT arm (Table 4); disease
control rate was similar: 82.4% (trabectedin arm) versus
86.5% (DXCT arm). Choi response criteria showed no
signiﬁcant diﬀerence between treatment arms: 37.3%
(trabectedin arm) versus 45.9% (DXCT arm).
3.6. Overall survival
Median follow-up for survival was 17.6 months. Of
121 randomised patients, 39 (63.9%, trabectedin) and
Table 1
Demographic and baseline characteristics (all randomised patients).
Characteristic Arm A (trabectedin) (n = 61) Arm B (DXCT) (n = 60)
n % n %
Race
Caucasian 53 86.9 54 90.0
Black 3 4.9 4 6.7
Asian/Oriental 2 3.3
Othera 3 4.9 2 3.3
Gender
Male 36 59.0 38 63.3
Female 25 41.0 22 36.7
Age (years)
Median (range) 47 (19–78) 49 (19–78)
ECOG PS
0 28 45.9 29 48.3
1 32 52.5 30 50.0
2 1 1.6 1 1.7
Tumour diagnosis (external pathology review)
MRCL 23 37.7 17 28.3
Other TRSb 28 45.9 20 33.3
Not conﬁrmedc 10 16.4 23 38.3
Primary tumour site
Lower extremity 39 63.9 37 61.7
Trunk/abdominal wall 2 3.3 10 16.7
Upper extremity 8 13.1 1 1.7
Face and neck 2 3.3 1 1.7
Other 10 16.4 11 18.3
Extent of disease
Metastatic 43 70.5 47 78.3
Locally advanced 18 29.5 13 21.7
No. of sites
Median (range) 2 (1–8) 2 (1–5)
Most common sites of disease
Soft tissue 33 54.1 33 55.0
Lung 29 47.5 29 48.3
Lymph node 17 27.9 11 18.3
Previous therapy
Radiotherapy 24 39.3 21 35.0
Surgery
Radical 32 52.5 36 60.0
Palliative 5 8.2 12 20.0
Anticancer therapy 1d 1.6 5e 8.3
Data shown are n of patients (%) except for median and range.
ECOG PS, Eastern Cooperative Oncology Group performance status; DXCT, doxorubicin-based chemotherapy; MRCL, myxoid/round cell
liposarcoma; TRS, translocation-related sarcomas.
a Hispanic (n = 3), North African and unknown.
b Synovial sarcoma (n = 24), extraskeletal myxoid chondrosarcoma (n = 7), clear cell sarcoma (n = 7), alveolar soft part sarcoma (n = 4), low
grade endometrial stromal sarcoma (n = 4) and desmoplastic small round cell tumour (n = 2).
c No conﬁrmation of diagnosis by the central laboratory was due to wrong diagnosis in 4 (7%) and 9 patients (15%) in trabectedin and DXCT
arms; no evidence of translocation in 3 (5%) and 2 patients (3%) and lack of available material for central review in 3 (5%) and 12 patients (20%),
respectively.
d Patients with endometrial stromal sarcoma who had previously received hormonal therapy.
e Three patients were previously treated with chemotherapy; these three cases were considered protocol deviations. The other two cases consisted
of one patient with endometrial stromal sarcoma who had previously received hormonal therapy, and one patient with clear cell sarcoma who had
previously received melphalan as locoregional therapy.
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Although these preliminary survival data did not
show signiﬁcant diﬀerences between therapies:HR = 0.77 (95% CI, 0.4–1.4) (p = 0.3672), survival
curves separated in favour of trabectedin after month
20 (Fig. 3).
Fig. 2. Kaplan–Meier plot of progression-free survival (PFS). N, number of patients; C, censored patients. Arm A (trabectedin); Arm B
(doxorubicin-based chemotherapy (DXCT)). (a) Eﬃcacy population, independent review. (b) All randomised patients, investigators’ assessment.
Data shown in the bottom of each ﬁgure are medians (95% conﬁdence interval (CI)).
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Most frequent grade P3 treatment-related AEs were
fatigue (n = 4; 6.6%) in trabectedin arm, and febrile
neutropenia (n = 7; 12.3%) and mucositis (n = 5; 8.8%)
in DXCT arm (Table 5). One death occurred in each
arm as outcome of a treatment-related event:
rhabdomyolysis (trabectedin) and pneumonia (DXCT).
Neutropenia was a common laboratory abnormality
in both treatment arms, and the main reason foradministration delays. Incidence of grade 3/4 neutrope-
nia was higher in DXCT arm (75.0% versus 55.0% in
trabectedin arm) (Table 5), but was generally well con-
trolled with growth factors (G-CSF), administered to
61.4% of patients, while in the trabectedin arm it was
more frequently managed with drug administration
delay until neutrophil count recovery (49.2% of patients
received G-CSF). Neutropenia associated with trabect-
edin followed a predictable reversible pattern, and was
uncomplicated (rarely associated with fever or
Table 2
Progression-free survival in the eﬃcacy population (independent review) and in all randomised patients (investigators’ assessment).
Arm A (trabectedin) Arm B (DXCT) LR (p-value) HR (95% CI) (p-value)
PFS, months (eﬃcacy population, independent review)
n of patients 51 37
Number of events, n (%) 16 (31.4%) 13 (35.1%)
Censored 35 (68.6%) 24 (64.9%)
Median (95% CI) 18.8 (5.7-nr) 8.3 (7.1–25.0) p = 0.9573 aHR b: 0.86 95% CI (0.4–1.8) (p = 0.6992)
PFS, months (all randomised patients, investigators’ assessment)
n of patients 61 60
Number of events, n (%) 29 (47.5%) 26 (43.3%)
Censored 32 (52.5%) 34 (56.7%)
Median (95% CI) 16.1 (5.5–21.9) 8.8 (5.5–12.7) p = 0.5533 cHR b: 0.85 95% CI (0. 5–1.5) (p = 0.5551)
CI, conﬁdence interval; DXCT, doxorubicin-based chemotherapy; HR, hazard ratio; LR, log rank; nr, not reached; PFS, progression-free survival.
a Stratiﬁed log rank test.
b HR: Arm A (trabectedin) compared to Arm B (DXCT). HR and p-value determined by Cox regression.
c Unstratiﬁed log rank test.
Table 3
Censoring reasons.
Arm A (trabectedin) (n = 51) Arm B (DXCT) (n = 37)
n % n %
Eﬃcacy population, independent review
Surgery 12 23.5 6 16.2
Chemotherapy 6 11.8 7 18.9
Radiotherapy 3 5.9 2 5.4
Last tumour assessmenta 12 23.5 5 13.5
Otherb 2 3.9 4 10.8
Total 35 68.6 24 64.9
Arm A (trabectedin) (n = 61) Arm B (DXCT) (n = 60)
n % n %
All randomised patients, investigators’ assessment
Surgery 11 18.0 12 20.0
Chemotherapy 5 8.2 4 6.7
Radiotherapy 3 4.9 6 10.0
Last tumour assessmenta 9 14.8 6 10.0
Otherb 4 6.6 6 10.0
Total 32 52.5 34 56.7
DXCT, doxorubicin-based chemotherapy.
a Patients still on treatment or in follow-up for disease assessments or with event out of study window.
b Censored at randomisation (e.g. untreated) or withdrawn due to related/unrelated adverse event or refusal before treatment onset/disease
progression or new treatment out of study window.
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trabectedin (1.6%) versus seven patients (12.3%) with
DXCT (Table 5). Incidence or severity of neutropenia
did not worsen in patients with most prolonged trabect-
edin treatment.
As expected, most common severe non-haematologi-
cal laboratory abnormality associated with trabectedin
was transaminases elevation, which occurred infre-
quently with DXCT (53.3% for ALT and 33.3% for
AST with trabectedin versus 1.9% for both ALT and
AST with DXCT). In agreement with previous trials,
severe transaminase increases had a transient pattern,
with a peak elevation on Day 8 and return to grade
<1 before Day 22 of each cycle, and showed a clear
trend to reduction in subsequent cycles of treatment.4. Discussion
Advanced STS are a heterogeneous group of tumours
that require medical treatment tailored according to his-
tological and molecular subtypes. Until now, no clinical
trials have investigated a novel treatment option in STS
with translocations that produce new or deregulated
transcription factors. This clinical trial was designed to
evaluate trabectedin versus DXCT as ﬁrst-line therapy
in unresectable locally advanced or metastatic,
pathologically conﬁrmed TRS by means of externally
assessed PFS. To date, no other phase III randomised
trials have been conducted comparing ﬁrst-line standard
doxorubicin or doxorubicin plus ifosfamide versus other
therapies in adult STS; only one phase II randomised
Table 4
Response rate in the eﬃcacy population (independent review).
Arm A (trabectedin) (n = 51) Arm B (DXCT) (n = 37) p-Value a
n % n %
Best objective response (RECIST)
PR 3b 5.9 10c 27.0
SD 39 76.5 22 59.5
PD 6 11.8 1 2.7
NE 3 5.9 4 10.8
Objective response rate (95% CI) 5.9% (1.2–16.2%) 27.0% (13.8–44.1%) 0.0123
Best response (Choi criteria)
PR 19 37.3 17 45.9
SD 5 9.8 2 5.4
PD 5 9.8 1 2.7
NE 22 43.1 17 45.9
Choi response rate (95% CI) 37.3% (24.1–51.9%) 45.9% (29.5–63.1%) 0.5109
CI, conﬁdence interval; DXCT, doxorubicin-based chemotherapy; MRCL, myxoid/round cell liposarcoma; NE, not evaluable; PD, progressive
disease; PR, partial response; SD, stable disease.
a Fisher’s exact test.
b PRs were observed in two patients with MRCL and in one patient with synovial sarcoma.
c PRs were observed in ﬁve patients with MRCL, four patients with synovial sarcoma and one patient with desmoplastic small round cell tumour.
Fig. 3. Kaplan–Meier plot of overall survival (OS) in all randomised patients. N, number of patients; C, censored patients. Arm A (trabectedin);
Arm B (doxorubicin-based chemotherapy (DXCT)). Data shown in the bottom of ﬁgure are medians (95% conﬁdence interval (CI)).
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with the ﬁrst stage, to be expanded in the second stage,
depending on results of interim analysis. For this interim
evaluation, target population was 80 evaluable patients,
and 45 PFS events were expected. The analysis had to be
conducted before reaching this event rate. Finally, 29
independently assessed PFS events were reached from
88 evaluable patients in May 2013 (55 PFS events in
all randomised patients). High attrition rate of evaluable
patients from all randomised populations (27.3%) due to
inaccurate diagnosis and/or lack of speciﬁctranslocation, together with high censoring rate (67.0%
in eﬃcacy population) resulted in fewer PFS events than
expected and, therefore, the analysis was underpowered
for statistical comparisons. First-line setting largely con-
tributed to high censoring. Patients suitable for surgery
after several treatment cycles underwent tumour
removal in both arms and, in Arm B, many patients
who completed 6–8 DXCT cycles per protocol received
a new anticancer therapy. As a consequence, results of
this trial do not allow conﬁrming superiority of either
treatment arm as ﬁrst-line chemotherapy in this sarcoma
Table 5
Treatment-related adverse events occurring in P10% of patients in any of treatment arms.
Arm A (trabectedin) (n = 61) Arm B (DXCT) (n = 57)
NCI-CTCAE gradea NCI-CTCAE gradea
1/2 3/4 1/2 3/4
n % n % n % n %
Abdominal pain 6 9.8 1 1.6 2 3.5 1 1.8
Alopecia 1 1.6 – – 25 43.9 – –
ALT increased 24 40.0 32 53.3 20 37.0 1 1.9
AP increased 34 56.7 3 5.0 21 38.9 – –
Anaemia 46 75.4 10 16.4 42 75.0 9 16.1
Anorexia 14 23.0 1 1.6 12 21.1 – –
AST increased 31 51.7 20 33.3 20 37.0 1 1.9
Constipation 12 19.7 – – 8 14.0 – –
CPK increased 20 34.5 5 8.6 4 8.2 2 4.1
Creatinine increased 12 19.7 3 4.9 4 7.4 1 1.9
Diarrhoea 10 16.4 – – 10 17.5 1 1.8
Dysgeusia 4 6.6 – – 6 10.5 – –
Fatigue 36 59.0 4 6.6 35 61.4 1 1.8
Febrile neutropenia – – 1 1.6 – – 7 12.3
Headache 8 13.1 – – 8 14.0 – –
Leukopaenia 30 49.2 18 29.5 17 30.4 33 58.9
Mucositis 3 4.9 1 1.6 15 26.3 5 8.8
Nausea 42 68.9 1 1.6 37 64.9 – –
Neutropenia 15 25.0 33 55.0 6 10.7 42 75.0
Oral pain – – – – 8 14.0 – –
Pyrexia 4 6.6 – – 7 12.3 – –
Thrombocytopenia 16 26.2 10 16.4 21 37.5 8 14.3
Total bilirubin increased 12 20.0 1 1.7 7 13.0 – –
Vomiting 26 42.6 1 1.6 15 26.3 – –
Weight decreased 3 4.9 1 1.6 6 10.5 – –
ALT, alanine aminotransferase; AP, alkaline phosphatase; AST, aspartate aminotransferase; CPK, creatine phosphokinase; DXCT, doxorubicin-
based chemotherapy; MedDRA, Medical Dictionary for Regulatory Activities; NCI-CTCAE, National Cancer Institute-Common Toxicity Cri-
teria for Adverse Events.
a Haematological and biochemical laboratory abnormalities are shown regardless of their relationship to treatment. Denominators in some of
these abnormalities could vary because of missing data.
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PFS between trabectedin and DXCT arms in both pri-
mary and secondary eﬃcacy analyses. Current results
indicate that design of a trial in this patient population
and setting would require a much larger sample size
(>500 patients). Recruitment of this population was
not feasible in a realistic timeframe and IDMC recom-
mended ending the study in the ﬁrst stage.
Curative or palliative removal of tumour lesions,
which was the most common censoring reason, was
performed in a similar proportion of patients from
both arms in eﬃcacy population (23.5% in trabectedin
arm; 16.2% in DXCT arm) but specially in all random-
ised population (18.0% in trabectedin arm; 20.0% in
DXCT arm) may imply a similar clinical beneﬁt for
both treatments. Response rate was signiﬁcantly higher
in the DXCT arm, but did not appear to translate into
a long-term clinical beneﬁt. Indeed, 5 of 13 patients
who achieved a partial response in DXCT arm (all ran-
domised analysis) relapsed when left untreated. In
addition, disease control rate was similar with both
therapies: 82.4% (trabectedin) versus 86.5% (DXCT)
and Choi response assessment showed no signiﬁcantdiﬀerences between treatment arms. In this regard,
the method described by Choi has been previously sug-
gested to be more accurate than RECIST to predict
outcome in sarcomas [17,18]. Furthermore, preliminary
survival curves were overlapping and showed a trend
of better outcome for trabectedin after a certain time
point (month P20), thus supporting the advantage of
prolonged treatment in some TRS.
Safety proﬁle observed in this clinical trial was that
expected for both trabectedin and DXCT. Most
common side-eﬀects related to trabectedin were gas-
trointestinal and general disorders (nausea, fatigue,
vomiting and anorexia); these ﬁndings agree with pre-
vious phase II analyses [19]. Most common side-eﬀects
related to DXCT were gastrointestinal, general disor-
ders and skin and mucous membranes disorders (nau-
sea, fatigue, alopecia, mucositis, vomiting and
anorexia), which was also in line with the well-known
safety proﬁle of anthracyclines [20–22]. The number of
patients who discontinued therapy because of treat-
ment-related events was slightly higher in the
trabectedin arm: 18.6% versus 10.5% in DXCT arm.
Nevertheless, a considerable number of patients
1146 J.-Y. Blay et al. / European Journal of Cancer 50 (2014) 1137–1147receiving trabectedin were treated for prolonged peri-
ods of time due to lack of cumulative toxicities:P25%
receivedP 10 cycles, for a maximum of 31 cycles
(maximum of eight cycles with DXCT). This pro-
longed exposure compares favourably with standard
treatments in STS, as administration of anthracyclines
and ifosfamide is limited by cumulative cardiac toxic-
ity, and cumulative haematological and renal toxicity
[23]. Similar to previous randomised clinical trials
[16,24,25], ﬁrst-line doxorubicin was limited per proto-
col to 6–8 cycles of therapy. Thus, 26 of 57 patients
treated with DXCT (45.6%) stopped therapy due to
treatment completion (i.e. maximal cumulative dose
reached); and two additional patients stopped treat-
ment before completion because of decreased LVEF.
In addition, anthracyclines cannot be administered in
subsequent lines once the established threshold of
cumulative dose has been reached. Conversely,
absence of cardiac toxicity [26] or other cumulative
toxicities of trabectedin makes this agent suitable for
the maintenance of treatment while patients are
obtaining clinical beneﬁt. In this study, 20 of 33
DXCT patients who received post-study chemotherapy
were treated with trabectedin.
Grade 3/4 neutropenia was more common in DXCT
arm (75.0% versus 55.0% in trabectedin arm). A pooled
analysis from trabectedin phase II trials [19] showed a
similar rate of severe neutropenia (50.5%), while stan-
dard ﬁrst-line agents in STS, doxorubicin and ifosfa-
mide, induce substantially more severe haematological
toxicities. Randomised studies with doxorubicin
showed grade 3/4 neutropenia in 77% of patients, with
16–19% febrile neutropenia, and high-dose ifosfamide
caused neutropenia and infection in 20% and 4% of
patients, respectively [27,28]. Combination regimens
cause more severe haematological toxicity despite rou-
tine G-CSF support [28,29]. In spite of this, more
patients in the trabectedin arm had drug dose adjust-
ments, with a median relative dose intensity of 87.9%
versus 100% in DXCT arm, because neutropenia was
more frequently controlled with G-CSF in DXCT
arm, while it was managed with administration delay
in patients receiving trabectedin.
Most common laboratory disorder associated with
trabectedin was elevated transaminases, which is
uncommon in patients treated with DXCT. Incidence
of trabectedin associated grade 3/4 increase (53.3%
and 33.3% for ALT and AST, respectively) in this trial
was similar to those previously reported (51.2% for
ALT and 40.7% for AST) [19]. Transaminase increase
was the most frequent reason for dose reductions.
However, the occurrence of hepatobiliary adverse
events was low, further supporting the observation that
the liver dysfunction induced by trabectedin is mostly
transient, non-cumulative and mostly without clinical
consequences.In conclusion, this phase III randomised trial
performed in a selected subset of TRS showed no
signiﬁcant diﬀerences in PFS between the two arms,
but was underpowered due to the high rate of censoring.
Incidence and type of censure were well balanced
between treatment arms, with surgery before disease
progression as the most frequent reason. No statistically
signiﬁcant diﬀerence was observed in OS. Safety was the
expected for trabectedin and DXCT; no new safety sig-
nals were reported. Considering the limitations of the
current study, trabectedin showed eﬃcacy and a man-
ageable safety proﬁle in this patient population and
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